A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo

For Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (CA209-77T)

Study Name:
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (CA209-77T)

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

Study Dates:
September 16, 2019 - September 30, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Bristol Myers Squibb

ClinicalTrails.gov Identifier:
NCT04025879

Register for Trial
Freedom From Smoking | Virtual Training
, | Aug 04, 2021
Freedom From Smoking Facilitator Training
, | Aug 11, 2021